Growth Stocks: Eli Lilly, Novo Nordisk, VRTX
This is a Vertex news story, published by Yahoo Finance, that relates primarily to Novo Nordisk news.
Vertex news
For more Vertex news, you can click here:
more Vertex newsNovo Nordisk news
For more Novo Nordisk news, you can click here:
more Novo Nordisk newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
diabetes drug market. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest biotech stock news, Vertex Pharmaceuticals news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
weekly tirzepatide injectionsThe Motley Fool
•3 No-Brainer Stocks to Buy in September
73% Informative
Three Motley Fool contributors identified several stocks that fit this description.
Eli Lilly , Novo Nordisk , and Vertex Pharmaceuticals are no-brainer healthcare stocks to buy in September .
They say the stocks are highly profitable companies with strong growth prospects.
The Motley Motives: Eli Lilly continually gives investors reason to become even more bullish on its plentiful growth opportunities.
The U.S. Food and Drug Administration set a PDUFA date of Jan. 2, 2025 , to make an approval decision on Vertex 's newest CF therapy.
The FDA expects to announce its approval decision for suzetrigine in treating acute pain on Jan. 30, 2025 .
Vertex is evaluating two other drugs in pivotal clinical studies.
VR Score
62
Informative language
54
Neutral language
41
Article tone
formal
Language
English
Language complexity
45
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
9
Source diversity
2
Affiliate links
no affiliate links